ClinicalTrials.gg

Program

NAV-240

A development code.

Its studies are mostly in Hidradenitis Suppurativa, led by Navigator Medicines.

Furthest: phase 2, since Jan 26, 20263 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Navigator Medicines31 open or runningphase 2since Jan 26, 2026Dec 13, 2023Sep 2027phase 2 · NCT07384975

Also a collaborator on its studies: southern-star-research and imbiologics-corp.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2023First study: phase 1 study in HealthyFirst studyNCT06181786 · 40 enrolled · United States
  2. Mar 31, 2025Phase 1 study in Healthy VolunteersNCT06933043 · 24 enrolled · Australia
  3. Jan 26, 2026Phase 2 study in Hidradenitis SuppurativaPhase 2 reachedNCT07384975 · 150 planned · United States, Bulgaria, Canada and more

Ahead

  1. Sep 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07384975

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07384975Hidradenitis Suppurativa · United States, Bulgaria, Canada and more2RecruitingSep 2027150
NCT06933043Healthy Volunteers · Australia1CompletedNov 20, 202524
NCT06181786Healthy · United States1CompletedSep 4, 202440

How it is read

Names in the registry

  • “NAV-240”, 3 entries

Codes read as this program: NAV240.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.